Welcome to Ask Epista, a video podcast where our team of experts share Life Science industry knowledge, in short videos. We are dedicated to continuously improving compliance and business. This way, we believe we can help increase the contribution of Life Science to society.
Ask Epista tackles topics that help Life Science professionals drive innovations that improve health care around the world, today. Here’s a look at Season 1. Click on the boxes below (or just scroll down), to learn more about each episode.
IDMP is substantially more complex than the current xEVMPD legislation. And deadlines are quickly approaching, meaning the time to prepare for the complex compliance mandate is flying by. We’ve gathered expert advice to take you from basic understanding to creating business value with your efforts.
Join these episodes on IDMP topics:
This episode introduces IDMP (Identification of Medicinal Products) to those new to the topic. We’ll provide you with context, definitions, and examples of IDMP use cases. The goal is to help you better understand how IDMP could impact your Life Science company.
MAHs with products on the market in the European Union will be the first to use IDMP to communicate information about their products to the EMA (European Medicines Agency). Over the next few years, the EMA will roll out their first iteration of IDMP via their master data initiative, SPOR. In this video we ask MAIN5, our valued collaboration partner, how MAHs can best prepare for the changes that are coming and how to secure continuously improving compliance and business going forward.
About MAIN5: Founded in Frankfurt/Main in 2013, MAIN5 is a Germany-based consulting firm, primarily servicing global Top 50 organizations, with the ability to operate virtually anywhere in the world. Their 30+ consultants have a profound knowledge of the industry and specialize in designing and implementing initiatives of strategic relevance in Life Sciences. In addition to bringing perspective and experience, MAIN5’s team remains constantly flexible. This means that their clients are served by an agile, highly responsive network that can be drawn on this network to create the team with the perfect fit for the job. To learn more about MAIN5, visit their website here
This episode sets the coming European Medicines Agency IDMP requirements aside. Instead, we’ll focus on the impact that IDMP will bring to the collaboration partners of MAHs, and our recommended actions for them. This episode is designed for suppliers of drug products and related materials, and drug development companies. Watch to learn how you can best prepare for the changes that IDMP will bring to your collaboration with MAHs - and the opportunities for improvement that you’ll find, as well.
The MAH is obliged to comply with the health authorities’ IDMP requirements. But is that all there is to it? Can IDMP support and provide direction for strategic business development? In this video, we discuss additional benefits of IDMP and how it can drive harmonization and alignment strategies.
You have a lot of knowledge when it comes to raising money, drug development, and go-to-market strategies, but what about commercialization – specifically serialization? In this episode of Ask Epista, we share our expertise to get you to market faster with lower risk.
Christian Conradsen discusses how you can integrate serialization into your entire supply chain, as you’re creating it. Watch to learn more about:
We enjoy sharing our knowledge. Get in touch to find out how Epista can add value to your Life Science company.